Search

Your search keyword '"Bouchayer, D."' showing total 7 results
Start Over Author "Bouchayer, D."
7 results on '"Bouchayer, D."'

2. Posters

Author

Török, T., Kardos, A., Rudas, L., Paprika, D., McLuckie, A., Beale, R. J., Bihari, D., Keller, H., Seltzer, N., Weimer, A., Menning, H., Ulrich, P., Staedt, U., Kirschstein, W., Kasai, T., Endo, S., Arakawa, N., Sato, N., Suzuki, T., Taniguchi, S., Inada, K., Hiramori, K., Schmidt, W., Meineke, I., Nottrott, M., Frerichs, I., Müller, S., Hellige, G., De Blasio E., De Sio A., Sibilio G., Papa A., Golia D., Grassia V., Bove G., Zehelgruber, M., Mundigler, G., Christ, G., Merhaut, C., Klaar, U., Kratochwill, C., Hofmann, S., Siostrzonek, P., Suarez, F., Corrales, M., Rábago, R., Gonzalez-Arenas, P., Morales, R., Sanchez J., Fraile, J., Rey, M., Martinell, J., Niederst, P. -N., Mellwig, K. -P., Schmidt, H. K., Gleichmann, U., Körfer, R., Di Bartolomeo, S., Bertolissi, M., Nardi, G., De Monte, A., Janssens, U., Ochs, J. -G., Klues, H. G., Hanrath, P., Sajjanhar, T., Tibby, S. M., Hatherill, M., Anderson, D., Murdoch, I. A., Krivec, B., Voga, G., Žuran, I., Skale, R., Parežnik, R., Podbregar, M., Bonnefoy, E., Chevalier, P., Kirkorian, G., Guidolet, J., Marchand, A., Bouchayer, D., Marcaz, P. Bert, Touboul, P., Welte, T., Molling, J., Jepsen, M. S., Claus, G., Klein, H., Cinnella, G., Dambrosio, M., Brienza, N., Conte, M., Maggiore, S. M., Leone, A. M., Brienza, A., DiVenere, N., Vandewoude, K., Poelaert, J., Vogelaers, D., Garcia, R. Blanca, Buylaert, W., Roosens, C., Colardyn, F., Annane, D., Béllissant, E., Pussard, E., Asmar, R., Lacombe, F., Lanata, E., Madonna, O., Safar, M., Giudicelli, J. F., Raphael, J. C., Gajdos, Ph., Mattys, M., Dumont, L., Annaert, J. F., Mardirosoff, C., Goldstein, J., Verbeet, T., Massaut, J., Haas, N. A., Uhlemann, F., Daehnert, I., Berger, F., Stiller, B., Dittrich, S., Schulze-Neick, I., Eweit, P., Lange, P. E., Langenherp, C. J. M., Pietersen, H., Geskes, G., Wagenmakers, A., Soeters, P., Maggiorini, M., Brimioulle, S., Lejeune, P., Delcroix, M., Vermeulen, F., Stephanazzi, J., Naeije, R., Kunert, M., Stolzenburg, H., Scheuble, L., Emmerich, K., Ulbricht, L. J., Krakau, I., Gülker, H., Broch, M. J., Valentín, V., Murcia, B., Bartual, E., Málaga, A., Miralles, L. L., Valls, F., Wallin, C. J., Sidenö, B., Vaage, J., Leksell, L. G., Stuchlinger, H. G., Seidler, D., Hollenstein, U., Janata, K., Muellner, M., Loeffler, W., Gamper, G., Bur, A., Malzer, R., Laggner, A. N., Hirschl, M. M., Binder, M., Herkner, H., Bur, A., Laggner, A. N., Turani, F., Ceraso, C., Lironcurti, A., Senesi, P., Leonardis, C., Sabato, A. F., Pietersen H. G., Langenberg C. J. M., Geskes G., Wagenmakers A. J. M., de Lange S., Soeters P. B., Royira, A., Oussedik, L., Cambray, C., Glmeno, C., Cerda, M., Sanchez, Ma. A., Lesmes, A., Guerrero, M., Vigil, E., Ortega, F., Lucena, F., Righini, E. R., Alvisi, R., Marangoni, E., Gritti, G., Ordóñez, A., Hernández, A., Pérez-Bernal, J., Hinojosa, R., Borrego, J. M., Franco, A., López-Barneo, J., Pérez-Bernal, J., Gutiérrez, E., Hinojosa, R., Hernández, A., Borrego, J. M., Cerro, J., Rincón, D., Ordóñez, A., Martin, R., Saussine, M., Sany, C. L., Calvet, B., Raison, D., Frapier, J. M., Wallin, C. -J., Olsson, Å., Nordländer, R., Leksell, L. G., Vasilkov, V., Safronov, A., Marinchev, V., Rodrigues, A. C., Moraes, A., Galas, F., Angelim, V., Medeiros, C., Auler, J. O., Bellotti, G., Pilleggi, F., Carmona, M. J., Messias, E. R. R., Joseph, D., Baigorri, F., Artigas, A., Blanch, L., Wagner, F., Dandel, M., Günther, G., Schulze-Neick, I., Weng, Y., Loebe, M., Hetzer, R., Colreavy, F., Balea, M., Cahalan, M., Carpintero, JL., de la Fuente, M. C., Estecha, M. A., Molina, J. M., del Fresno, L. R., Daga, D., Toro, R., Poullet, A., de la Torre, M. V., Garcia, A. J., Michalopoulos, A., Rellos, K., Skambas, D., Liakopoulos, O., and Geroulanos, S.

Published
1996
Full Text
View/download PDF

3. Late Outcomes of Transcatheter Aortic Valve Replacement in High-Risk Patients: The FRANCE-2 Registry

Author

Gilard, M., Eltchaninoff, H., Donzeau-Gouge, P., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Tchetche, D., Carrie, D., Himbert, D., Albat, B., Cribier, A., Sudre, A., Blanchard, D., Rioufol, G., Collet, F., Houel, R., Dos Santos, P., Meneveau, N., Ghostine, S., Manigold, T., Guyon, P., Grisoli, D., Le Breton, H., Delpine, S., Didier, R., Favereau, X., Souteyrand, G., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Claudel, J. -P., Bourlon, F., Bertrand, B., Laskar, M., Iung, B., Bertrand, M., Cassagne, J., Boschat, J., Lusson, J. R., Mathieu, P., Logeais, Y., Bessou, J. -P., Chevalier, B., Farge, A., Garot, P., Hovasse, T., Morice, M. C., Romano, M., Gouge, P. D., Vahdat, O., Farah, B., Dumonteil, N., Fournial, G., Marcheix, B., Nataf, P., Vahanian, A., Leclercq, F., Piot, C., Schmutz, L., Aubas, P., du Cailar, A., Dubar, A., Durrleman, N., Fargosz, F., Levy, G., Maupas, E., Rivalland, F., Robert, G., Tron, C., Juthier, F., Modine, T., Van Belle, E., Banfi, C., Sallerin, T., Bar, O., Barbey, C., Chassaing, S., Chatel, D., Le Page, O., Tauran, A., Cao, D., Dauphin, R., Durand de Gevigney, G., Finet, G., Jegaden, O., Obadia, J. -F., Beygui, F., Collet, J. -P., Pavie, A., Pecheux, Bayet, Vaillant, A., Vicat, J., Wittenberg, O., Joly, P., Rosario, R., Bergeron, P., Bille, J., Gelisse, R., Couetil, J. -P., Dubois Rande, J. -L., Hayat, D., Fougeres, E., Monin, J. -L., Mouillet, G., Arsac, F., Choukroun, E., Dijos, M., Guibaud, J. -P., Leroux, L., Elia, N., Descotes, Genon, Chocron, S., Schiele, F., Caussin, C., Azmoun, A., Nottin, R., Tirouvanziam, A., Crochet, D., Gaudin, R., Roussel, J. -C., Bonnet, N., Digne, F., Mesnidrey, P., Royer, T., Stratiev, V., Bonnet, J. -L., Cuisset, T., Abouliatim, I., Bedossa, M., Boulmier, D., Verhoye, J. P., Delepine, S., Debrux, J. -L., Furber, A., Pinaud, F., Bezon, E., Choplain, J. -N., Bical, O., Dambrin, G., Deleuze, P., Jegou, A., Lusson, J. -R., Azarnouch, K., Durel, N., Innorta, A., Lienhart, Y., Roriz, R., Staat, P., Fabiani, J. -N., Lafont, A., Zegdi, R., Heudes, D., Kindo, M., Mazzucotelli, J. -P., Zupan, M., Ivascau, C., Lognone, T., Massetti, M., Sabatier, R., Huret, B., Hochart, P., Pecheux, Bouchayer, D., Gabrielle, F., Pelissier, F., Tremeau, G., Dreyfus, G., Eker, A., Habib, Y., Hugues, N., Mialhe, C., Chavanon, O., Porcu, P., Vanzetto, G., Banfi C., Massetti M. (ORCID:0000-0002-7100-8478), Gilard, M., Eltchaninoff, H., Donzeau-Gouge, P., Chevreul, K., Fajadet, J., Leprince, P., Leguerrier, A., Lievre, M., Prat, A., Teiger, E., Lefevre, T., Tchetche, D., Carrie, D., Himbert, D., Albat, B., Cribier, A., Sudre, A., Blanchard, D., Rioufol, G., Collet, F., Houel, R., Dos Santos, P., Meneveau, N., Ghostine, S., Manigold, T., Guyon, P., Grisoli, D., Le Breton, H., Delpine, S., Didier, R., Favereau, X., Souteyrand, G., Ohlmann, P., Doisy, V., Grollier, G., Gommeaux, A., Claudel, J. -P., Bourlon, F., Bertrand, B., Laskar, M., Iung, B., Bertrand, M., Cassagne, J., Boschat, J., Lusson, J. R., Mathieu, P., Logeais, Y., Bessou, J. -P., Chevalier, B., Farge, A., Garot, P., Hovasse, T., Morice, M. C., Romano, M., Gouge, P. D., Vahdat, O., Farah, B., Dumonteil, N., Fournial, G., Marcheix, B., Nataf, P., Vahanian, A., Leclercq, F., Piot, C., Schmutz, L., Aubas, P., du Cailar, A., Dubar, A., Durrleman, N., Fargosz, F., Levy, G., Maupas, E., Rivalland, F., Robert, G., Tron, C., Juthier, F., Modine, T., Van Belle, E., Banfi, C., Sallerin, T., Bar, O., Barbey, C., Chassaing, S., Chatel, D., Le Page, O., Tauran, A., Cao, D., Dauphin, R., Durand de Gevigney, G., Finet, G., Jegaden, O., Obadia, J. -F., Beygui, F., Collet, J. -P., Pavie, A., Pecheux, Bayet, Vaillant, A., Vicat, J., Wittenberg, O., Joly, P., Rosario, R., Bergeron, P., Bille, J., Gelisse, R., Couetil, J. -P., Dubois Rande, J. -L., Hayat, D., Fougeres, E., Monin, J. -L., Mouillet, G., Arsac, F., Choukroun, E., Dijos, M., Guibaud, J. -P., Leroux, L., Elia, N., Descotes, Genon, Chocron, S., Schiele, F., Caussin, C., Azmoun, A., Nottin, R., Tirouvanziam, A., Crochet, D., Gaudin, R., Roussel, J. -C., Bonnet, N., Digne, F., Mesnidrey, P., Royer, T., Stratiev, V., Bonnet, J. -L., Cuisset, T., Abouliatim, I., Bedossa, M., Boulmier, D., Verhoye, J. P., Delepine, S., Debrux, J. -L., Furber, A., Pinaud, F., Bezon, E., Choplain, J. -N., Bical, O., Dambrin, G., Deleuze, P., Jegou, A., Lusson, J. -R., Azarnouch, K., Durel, N., Innorta, A., Lienhart, Y., Roriz, R., Staat, P., Fabiani, J. -N., Lafont, A., Zegdi, R., Heudes, D., Kindo, M., Mazzucotelli, J. -P., Zupan, M., Ivascau, C., Lognone, T., Massetti, M., Sabatier, R., Huret, B., Hochart, P., Pecheux, Bouchayer, D., Gabrielle, F., Pelissier, F., Tremeau, G., Dreyfus, G., Eker, A., Habib, Y., Hugues, N., Mialhe, C., Chavanon, O., Porcu, P., Vanzetto, G., Banfi C., and Massetti M. (ORCID:0000-0002-7100-8478)

Abstract

Background Transcatheter aortic valve replacement (TAVR) has revolutionized management of high-risk patients with severe aortic stenosis. However, survival and the incidence of severe complications have been assessed in relatively small populations and/or with limited follow-up. Objectives This report details late clinical outcome and its determinants in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry. Methods The FRANCE-2 registry prospectively included all TAVRs performed in France. Follow-up was scheduled at 30 days, at 6 months, and annually from 1 to 5 years. Standardized VARC (Valve Academic Research Consortium) outcome definitions were used. Results A total of 4,201 patients were enrolled between January 2010 and January 2012 in 34 centers. Approaches were transarterial (transfemoral 73%, transapical 18%, subclavian 6%, and transaortic or transcarotid 3%) or, in 18% of patients, transapical. Median follow-up was 3.8 years. Vital status was available for 97.2% of patients at 3 years. The 3-year all-cause mortality was 42.0% and cardiovascular mortality was 17.5%. In a multivariate model, predictors of 3-year all-cause mortality were male sex (p < 0.001), low body mass index, (p < 0.001), atrial fibrillation (p < 0.001), dialysis (p < 0.001), New York Heart Association functional class III or IV (p < 0.001), higher logistic EuroSCORE (p < 0.001), transapical or subclavian approach (p < 0.001 for both vs. transfemoral approach), need for permanent pacemaker implantation (p = 0.02), and post-implant periprosthetic aortic regurgitation grade ≥2 of 4 (p < 0.001). Severe events according to VARC criteria occurred mainly during the first month and subsequently in <2% of patients/year. Mean gradient, valve area, and residual aortic regurgitation were stable during follow-up. Conclusions The FRANCE-2 registry represents the largest database available on late results of TAVR. Late mortality is largely related to noncardiac

Published
2016

5. A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study.

Author

Frank D, Durand E, Lauck S, Muir DF, Spence M, Vasa-Nicotera M, Wood D, Saia F, Urbano-Carrillo CA, Bouchayer D, Iliescu VA, Saint Etienne C, Leclercq F, Auffret V, Asmarats L, Di Mario C, Veugeois A, Maly J, Schober A, Nombela-Franco L, Werner N, Gómez-Hospital JA, Mascherbauer J, Musumeci G, Meneveau N, Meurice T, Mahfoud F, De Marco F, Seidler T, Leuschner F, Joly P, Collet JP, Vogt F, Di Lorenzo E, Kuhn E, Disdier VP, Hachaturyan V, Lüske CM, Rakova R, Wesselink W, Kurucova J, Bramlage P, and McCalmont G

Subjects
Humans, Male, Female, Aged, 80 and over, Aged, Critical Pathways, Europe epidemiology, Postoperative Complications epidemiology, Postoperative Complications prevention & control, Patient Safety, Transcatheter Aortic Valve Replacement methods, Aortic Valve Stenosis surgery, Benchmarking, Length of Stay statistics & numerical data
Abstract

Background and Aims: There is significant potential to streamline the clinical pathway for patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of this study was to evaluate the effect of implementing BENCHMARK best practices on the efficiency and safety of TAVI in 28 sites in 7 European countries., Methods: This was a study of patients with severe symptomatic aortic stenosis (AS) undergoing TAVI with balloon-expandable valves before and after implementation of BENCHMARK best practices. Principal objectives were to reduce hospital length of stay (LoS) and duration of intensive care stay. Secondary objective was to document patient safety., Results: Between January 2020 and March 2023, 897 patients were documented prior to and 1491 patients after the implementation of BENCHMARK practices. Patient characteristics were consistent with a known older TAVI population and only minor differences. Mean LoS was reduced from 7.7 ± 7.0 to 5.8 ± 5.6 days (median 6 vs. 4 days; P < .001). Duration of intensive care was reduced from 1.8 to 1.3 days (median 1.1 vs. 0.9 days; P < .001). Adoption of peri-procedure best practices led to increased use of local anaesthesia (96.1% vs. 84.3%; P < .001) and decreased procedure (median 47 vs. 60 min; P < .001) and intervention times (85 vs. 95 min; P < .001). Thirty-day patient safety did not appear to be compromised with no differences in all-cause mortality (0.6% in both groups combined), stroke/transient ischaemic attack (1.4%), life-threatening bleeding (1.3%), stage 2/3 acute kidney injury (0.7%), and valve-related readmission (1.2%)., Conclusions: Broad implementation of BENCHMARK practices contributes to improving efficiency of TAVI pathway reducing LoS and costs without compromising patient safety., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

6. [Predictive factors of induction of ventricular arrhythmia under amiodarone].

Author

Bourret N, Kirkorian G, Chevalier P, Bellon C, Richalet C, Bouchayer D, Bonnefoy E, and Touboul P

Subjects
Adult, Aged, Death, Sudden, Cardiac epidemiology, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Patient Care Planning, Predictive Value of Tests, Recurrence, Retrospective Studies, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular mortality, Tachycardia, Ventricular physiopathology, Treatment Outcome, Ventricular Fibrillation diagnosis, Ventricular Fibrillation mortality, Ventricular Fibrillation physiopathology, Amiodarone therapeutic use, Anti-Arrhythmia Agents therapeutic use, Cardiac Pacing, Artificial, Tachycardia, Ventricular drug therapy, Ventricular Fibrillation drug therapy
Abstract

A good result of electrophysiological investigations under amiodarone therapy distinguishes a low risk group of patients with malignant ventricular arrhythmias. The authors set out to determine the factors predictive of this response in order to identify patients better protected by amiodarone at an earlier stage. Fourty-five patients with an average age of 56 years, were referred for evaluation of severe ventricular arrhythmias, monomorphic ventricular tachycardia being inducible during electrophysiological investigation in all cases before treatment. Amiodarone was prescribed orally at degressive doses. A control electrophysiological study was performed 4 to 6 weeks later. Eighteen patients (40%) were considered to be responders (absence of inducible ventricular arrhythmia or inducible non-sustained tachycardia or tachycardia with a cycle length increased by over 100 ms with respect to the base-line study). The other 27 patients were considered to be non-responders. No clinical or paraclinical parameter was found to distinguish responders from non-responders. The authors conclude that the data obtained before control electrophysiological investigation under amiodarone does not allow prediction of the response to this drug. The search for early prognosis of the efficacy of amiodarone in preventing ventricular arrhythmias therefore requires electrophysiological investigation after impregnation.

Published
1996

7. [Thrombosis on the mitral valve prosthesis and disseminated cancer: treatment by fibrinolysis].

Author

Chevalier P, Bonnefoy E, Kirkorian G, Richalet C, Bourret N, Bouchayer D, and Touboul P

Subjects
Breast Neoplasms pathology, Female, Humans, Middle Aged, Mitral Valve, Neoplasm Metastasis, Shock, Cardiogenic etiology, Thrombolytic Therapy, Thrombosis etiology, Treatment Outcome, Fibrinolytic Agents therapeutic use, Heart Valve Prosthesis adverse effects, Streptokinase therapeutic use, Thrombosis drug therapy
Abstract

The authors report the case of a 63-year-old woman with occlusive thrombosis of a mitral valve prosthesis and cardiogenic shock successfully treated by systemic thrombolytic therapy. This treatment was given despite metastatic hepatic and bone breast cancer. This, and other recently reported cases, argues in favour of widening the indication of thrombolysis as treatment of first intention in cases of obstruction of atrioventricular valve prostheses. Nevertheless, the relative safety of surgical treatment and the risk of systemic thromboembolism of thrombolysis, incites caution and reservation of medical therapy for carefully selected patients.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results